Author

Douglas C. Wolf 1

1 Atlanta Gastroenterology Associates ,Atlanta,United States

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF OZANIMOD, AN ORAL S1P RECEPTOR MODULATOR, IN MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS OF THE MAINTENANCE PERIOD OF THE TOUCHSTONE STUDY

William Sandborn, Brian G. Feagan, Douglas C. Wolf, Geert R. D'Haens, Severine Vermeire, Stephen B Hanauer, Subrata Ghosh, Heather Smith, Matt Cravets, Paul A. Frohna, Richard Aranda, Sheila Gujrathi, Allan Olson

CHARACTERISTICS OF ULCERATIVE COLITIS PATIENTS BY URGENCY OF DEFECATION AT ENROLLMENT IN THE CORRONA INFLAMMATORY BOWEL DISEASE REGISTRY

Douglas C. Wolf

CHARACTERISTICS OF ULCERATIVE COLITIS PATIENTS BY URGENCY OF DEFECATION AT ENROLLMENT IN THE CORRONA INFLAMMATORY BOWEL DISEASE REGISTRY

Douglas C. Wolf, April Naegeli, Mingyang Shan, Theresa Hunter Gibble, Angelina Sontag, Page Moore, Rachel Mackey, Margaux Crabtree, Raymond Cross

CLINICAL BENEFIT OF ADALIMUMAB DOSE ADJUSTMENT FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE IN EXTEND

Jean-Frederic Colombel, Paul Rutgeerts, William Sandborn, Douglas C. Wolf, Walter Reinisch, Gert Van Assche, Samantha Eichner, Joel Petersson, Anne M. Robinson, Roopal B Thakkar

Clinical Remission Demonstrated with Oral Ozanimod in the Overall Population and Across Multiple Subgroups of Patients with Moderately to Severely Active Ulcerative Colitis in the TOUCHSTONE Trial

Brian G. Feagan, William Sandborn, Geert R. D'Haens, Stephen B Hanauer, Douglas C. Wolf, Severine Vermeire, Subrata Ghosh, AnnKatrin Petersen, Steven Ye Hua, Kevin Shan, Jerry Liu

EFFECTS OF OZANIMOD ON CIRCULATING LYMPHOCYTES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: FLOW CYTOMETRY RESULTS FROM THE STEPSTONE PHASE 2 STUDY

Sarah Harris, William Sandborn, Brian G. Feagan, Stephen B Hanauer, Severine Vermeire, Subrata Ghosh, Wenzhong Liu, Douglas C. Wolf, Geert D’Haens

EFFICACY OF USTEKINUMAB FOR INDUCTION AND MAINTENANCE OF ENDOSCOPIC HEALING IN PATIENTS WITH CROHN?S DISEASE

Paul Rutgeerts, Christopher Gasink, Daphne Chan, Yinghua Lang, Paul Pollack, Stephen B Hanauer, Douglas C. Wolf, Douglas Jacobstein, Jewel Johanns, Philippe Szapary, Brian G. Feagan, William Sandborn

LONG-TERM SAFETY AND EFFICACY OF OZANIMOD IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE TOUCHSTONE OPEN-LABEL EXTENSION

William Sandborn, Brian G. Feagan, Stephen B Hanauer, Severine Vermeire, Subrata Ghosh, Wenzhong Liu, AnnKatrin Petersen, Lorna Charles, Vivian Huang, Keith Usiskin, Douglas C. Wolf, Geert R. D'Haens

OZANIMOD AS INDUCTION THERAPY IN MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRUE NORTH STUDY

William Sandborn, Geert R. D'Haens, Douglas C. Wolf, Stephen B Hanauer, Igor Jovanovic, Subrata Ghosh, AnnKatrin Petersen, Steven Y Hua, Ji Hwan Lee, Lorna Charles, Keith Usiskin, Silvio Danese, Brian G. Feagan

OZANIMOD AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRUE NORTH STUDY

Silvio Danese, Brian G. Feagan, Douglas C. Wolf, Stephen B Hanauer, Igor Jovanovic, Subrata Ghosh, AnnKatrin Petersen, Steven Y Hua, Ji Hwan Lee, Lorna Charles, Denesh Chitkara, William Sandborn, Geert D’Haens

Item 1 - 10 / 12
1
2